Discovery leads to development of new drug for inflammatory diseases

September 1, 2017 by Julia Short, Cardiff University

A lipid (fat) whose anti-inflammatory activities were discovered by Cardiff University, with colleagues from Universities of Pittsburgh, Oregon and Michigan, is being developed into a new drug for the treatment of diseases that currently have limited therapeutic options.

Detailed study of the lipid by the groups of Professor Valerie O'Donnell (Cardiff University) and Bruce Freeman (University of Pittsburgh) found it could dampen down inflammation in circulating blood cells, making it an excellent candidate for development into a drug for several inflammatory diseases.

Now under license to the biopharmaceutical company Complexa, the new drug - CXA-10 - has just received $62M of funding to enter phase 2 clinical trials where it will be tested on patients with FSGS (a rare disease that attacks the kidneys) and (a progressive disease caused by narrowing or tightening of the pulmonary arteries).

Professor Valerie O'Donnell, Co-Director of Systems Immunity Research Institute at Cardiff University, said: "The discovery that this lipid has potent anti-inflammatory activity is now being used to develop therapies that could significantly improve the lives of people with life-threatening diseases."

Josh Tarnoff, President and Chief Executive Officer of Complexa, added: "CXA-10 has already demonstrated disease-modifying effects in preclinical tests and has great potential to do the same in inflammatory conditions such as FSGS and PAH, in which many patients fail to respond to existing treatment options."

FSGS is a that leads to scarring in the kidney, reducing kidney function and causing the majority of sufferers to develop end-stage renal disease. Once dialysis is required, the is only eight years. There are currently no approved for FSGS patients, who often endure long courses of high-dose steroids without responding. CXA-10 is being investigated as a steroid-sparing agent in recently diagnosed patients.

Pulmonary arterial hypertension is caused by changes to the - the blood vessels that carry blood from the heart to the lungs. The walls of the arteries become thick and stiff, narrowing the space for blood to pass through and increasing blood pressure. The disease leads to exercise intolerance, breathlessness and heart failure. In the UK, around 6,000-7,000 people have . It's thought that more people have the condition and haven't been diagnosed.

Explore further: Researchers find beta blockers have positive effect in pulmonary arterial hypertension

Related Stories

Researchers find beta blockers have positive effect in pulmonary arterial hypertension

August 31, 2017
A team of Cleveland Clinic researchers found that a common heart disease medication, beta blockers, may help treat pulmonary arterial hypertension (PAH), a debilitating lung disease.

New biomarkers for improved treatment of severe heart- and lung disease

January 18, 2016
New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary ...

Positive results for new oral drug for pulmonary hypertension

December 23, 2015
Living with pulmonary arterial hypertension is challenging, but the chore of treating the rare heart disease may change following promising clinical trial data to be published in the Dec. 24 issue of the New England Journal ...

Circulating blood factor linked with a leading cause of kidney failure

November 8, 2012
Patients with a disease that is a leading cause of kidney failure tend to have high levels of a particular factor circulating in their blood, according to a study appearing in an upcoming issue of the Journal of the American ...

Pulmonary artery stiffening is an early driver of pulmonary hypertension

June 2, 2016
Pulmonary hypertension is an abnormal elevation of pressure in the pulmonary circulation that results in stress on the heart and remodeling of blood vessels in the lung. Pulmonary hypertension is caused by a variety of factors, ...

Recommended for you

Machine learning tool predicts the potential of peptides as immune activators

October 23, 2018
The immune system keeps T cells under control by regulating precisely when they can respond to a pathogen. For instance, helper T cells only turn "on" if other immune cells, such as antigen-presenting cells (APCs) present ...

A new mechanism in the control of inflammation

October 18, 2018
After infection or tissue injury, the inflammatory immune response attacks the infection and repairs the damaged tissue. However, sometimes excess inflammation can have the opposite effect, increasing injury in a process ...

Sugar, a 'sweet' tool to understand brain injuries

October 15, 2018
Australian researchers have developed ground-breaking new technology which could prove crucial in treating brain injuries and have multiple other applications, including testing the success of cancer therapies.

Scientists reveal new cystic fibrosis treatments work best in inflamed airways

October 11, 2018
A new UNC School of Medicine study shows that two cystic fibrosis (CF) drugs aimed at correcting the defected CFTR protein seem to be more effective when a patient's airway is inflamed. This is the first study to evaluate ...

Microbiome profiling reveals associations with ulcerative colitis severity, treatment

October 11, 2018
A study of gut microbes from more than 400 children points to how the microbiome behaves in this inflammatory bowel disease.

Genomic study finds a new role for microRNAs as predictors of Crohn's disease progression

October 4, 2018
Crohn's disease is a lifelong condition characterized by a fluctuating course of gastro-intestinal inflammation with repeated flares and remissions. Any part of the alimentary tract from the mouth to the anus can be affected ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.